Roche Holding AG (ETR:RHO)
Germany · Delayed Price · Currency is EUR | Market Cap | 272.16B +10.2% |
| Revenue (ttm) | 68.05B +1.5% |
| Net Income | 13.83B +55.6% |
| EPS | 17.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 19.67 |
| Forward PE | 15.49 |
| Dividend | 11.96 (3.40%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 308 |
| Average Volume | 848 |
| Open | 351.00 |
| Previous Close | 351.80 |
| Day's Range | 351.00 - 353.60 |
| 52-Week Range | 272.60 - 420.80 |
| Beta | n/a |
| RSI | 35.11 |
| Earnings Date | Apr 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Vector Institute Extends Collaboration With Roche
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Today, the Vector Institute announced the renewal of its collaboration with Roche through 2030, extending a connection that has advanced artificial intellig...
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis , and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident a...
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Basel, 23 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the inauguration of the new research home for the Institute of Human Biology. The opening marks a significant milestone in Roc...
Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says
The company discontinued developing emugrobart after two studies showed the drug didn't achieve intended outcomes.
Roche Bets Splits in Obesity Market Will Open Door to New Entrants
EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the likes of Eli Lilly and Novo Nordisk.
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
Roche's Ionify® steroid assays join its Vitamin D Total test as the latest mass spectrometry tests to receive CLIA 'moderate complexity' classification. The expanded steroid menu brings the sensitivit...
Roche Bought Thousands Of Nvidia AI Chips To Speed Up Drug Development
Pharmaceutical giant Roche said today it is launching a new large-scale “AI factory” with thousands of the latest Nvidia chips to accelerate the development of new drugs and diagnostics.
Roche ramps up AI computing capacity with Nvidia chip expansion
Swiss drugmaker Roche said on Monday it had expanded its artificial intelligence computing capacity with more than 2,100 Nvidia chips to support drug and diagnostics development.
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that an expansion of its global AI infrastructure, deploying a large-scale AI factory powered by a full stack of the latest-ge...
Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4 genetic variant using a simple blood sample. The test offers a fast, reliable a...
Roche Annual General Meeting 2026
Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting. The 594 shareholders in ...
Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration
GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes m...
Strait of Hormuz will partially reopen in 2-3 weeks: David Roche
Quantum Strategy' David Roche says he expects oil reserves can sufficiently support world demand, and that the 'world won't run out of oil'. He also explains why he believes Iran can't afford to escal...
Roche shares drop as oral breast cancer drug fails in trial
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate giredestrant against a common form of breast cancer can help newly diagnosed pa...
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating i...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbocicli...
2 Underrated Weight Loss Stocks to Buy Now
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duti...
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus ery...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial
Genentech, part of Roche , said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 peopl...